About this trial
One third of women with gestational diabetes (GDM), diabetes diagnosed during pregnancy, have abnormal glucose levels within 3 years after pregnancy, but follow up is low. Continuous glucose monitors (CGM), a small sensor inserted under the skin, may be able to screen women with GDM for diabetes risk. The investigators will ask postpartum women to use CGM at 6-8 weeks postpartum and answer surveys about quality of life after wearing the CGM. The investigators will collect data on blood glucose trends for future studies if participants find CGM use acceptable. The investigators hope to learn if CGM could improve postpartum follow up experiences for people with recent GDM.
Eligibility criteria
Qualifiers
Women with a viable singleton intrauterine pregnancy
Able to understand the study, and having understood, provide written informed consent in English
Recent pregnancy affected by gestational diabetes
Disqualifiers
Pregestational Diabetes (Type I or Type II)
Continued use of diabetes medications (including metformin and insulin) immediately after delivery
Preterm delivery (< 37 weeks gestation)
Twin or higher order gestation
Trial design
Treatments tested in this trial
- Continuous glucose monitor
- Oral Glucose Tolerance Test
- Hemoglobin A1c
Treatment groups
Locations
1Sponsors and collaborators
Ohio State University
Lead sponsor
DexCom, Inc.
Collaborator